title: Pretreatment Serum Albumin Level is an Independent Prognostic Factor in Patients with Stage IIIB Non-Small Cell Lung Cancer: A Study of the Turkish Descriptive Oncological Researches Group.
abstract: BACKGROUND
  Several prognostic factors have been studied in NSCLC, although it is unknown which is most useful. In this study, we aimed to investigate whether pre-treatment serum albumin level has prognostic value in patients with Stage IIIB NSCLC.
  
  
  METHODS
  This cross-sectional study included a total of 204 patients with Stage IIIB NSCLC who met the inclusion criteria. Pre-treatment serum albumin levels and demographic, clinical, and histological characteristics, as well as laboratory variables were recorded. A cut-off value was defined for serum albumin level and the patients were stratified into four groups on thios basis.
  
  
  RESULTS
  The majority of the patients was males and smokers, with a history of weight loss, and squamous histological type of lung cancer. The mean serum albumin level was 3.2±1.7 g/dL (range, 2.11-4.36 g/dL). A cut-off value 3.11 g/dL was set and among the patients with a lower level, 68% had adenocarcinoma and 82% were smokers. The patients with low serum albumin levels had a lower response rate to e first-line chemotherapy with a shorter progression-free survival and overall survival. Multivariate analysis showed that low serum albumin level was an independent poor prognostic factor for NSCLC.
  
  
  CONCLUSIONS
  This study results suggest that low serum albumin level is an independent poor prognostic factor in patients with Stage IIIB NSCLC, associated with reduction in the response rate to first-line therapy and survival rates.
authors: Department of Medical Oncology, Sitki Kocman University Faculty of Medicine, Mugla, Turkey E-mail : mugla.medicaloncology@gmail.com.
authors: Ozgur
authors: O
authors: Tanriverdi
authors: Nilufer
authors: N
authors: Avci
authors: Esin
authors: E
authors: Oktay
authors: Serdar
authors: S
authors: Kalemci
authors: Kezban Nur
authors: KN
authors: Pilanci
authors: Suna
authors: S
authors: Cokmert
authors: Serkan
authors: S
authors: Menekse
authors: Muharrem
authors: M
authors: Kocar
authors: Cenk Ahmet
authors: CA
authors: Sen
authors: Tulay
authors: T
authors: Akman
authors: Cetin
authors: C
authors: Ordu
authors: Gamze
authors: G
authors: Goksel
authors: Nezih
authors: N
authors: Meydan
authors: Sabri
authors: S
authors: Barutca
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy / Q000401:mortality / Q000556:secondary*; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D018196:Carcinoma, Adenosquamous / Q000097:blood / Q000188:drug therapy / Q000401:mortality / Q000556:secondary*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000188:drug therapy / Q000401:mortality / Q000556:secondary*; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000188:drug therapy / Q000401:mortality / Q000556:secondary*; D003430:Cross-Sectional Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D008207:Lymphatic Metastasis; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D012709:Serum Albumin / Q000032:analysis*; D015996:Survival Rate; D014421:Turkey
chemical_list: D014408:Biomarkers, Tumor; D012709:Serum Albumin